This inventor holds 1 USPTO granted patent. Top assignee: Schering Aktiengesellschaft. Active years: 2001.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2001
Title: The Innovative Contributions of Márta Szöllosy
Introduction
Márta Szöllosy is a notable inventor based in Budapest, Hungary. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target the central nervous system. His work has implications for treating various neurological disorders.
Latest Patents
Márta Szöllosy holds a patent for "Condensed 2,3-benzodiazepine derivatives and their use as AMPA-receptor inhibitors." This invention concerns compounds of formula (I), where R, R, R, and R can be hydrogen or different substituents; X can be hydrogen or halogen; Y can be C1-alkoxy or X and Y together can mean —O—(CH2)—O—. The variable n can be 1, 2, or 3, and A, together with nitrogen, forms a saturated or unsaturated five-member heterocycle that may contain between 1 and 3 nitrogen atoms, an oxygen atom, and/or one or two carbonyl groups. These compounds are significant due to their non-competitive inhibition of AMPA receptors, making them potential medicaments for treating diseases of the central nervous system. He has 1 patent to his name.
Career Highlights
Márta Szöllosy is associated with Schering Aktiengesellschaft, a company known for its research and development in pharmaceuticals. His work at the company has allowed him to focus on innovative solutions in the field of medicine.
Collaborations
Márta has collaborated with notable colleagues such as István Ling and Sándor Sólyom. Their combined expertise has contributed to advancements in their respective fields.
Conclusion
Márta Szöllosy's contributions to medicinal chemistry and his innovative patent for AMPA-receptor inhibitors highlight his role as a significant inventor in the field. His work continues to pave the way for new treatments for central nervous system diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile